Hepatitis C Clinical Trial
— SCALE-COfficial title:
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
NCT number | NCT03776760 |
Other study ID # | VHCRP1802 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 28, 2019 |
Est. completion date | August 2022 |
A community-based "test and treat" intervention integrating point-of-care HCV RNA testing, non-invasive liver disease assessment and linkage to care will lead to a reduction in HCV prevalence among people attending Aboriginal health services.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | August 2022 |
Est. primary completion date | August 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age or older; - voluntarily signed the informed consent form. Exclusion Criteria: - Pregnant women. |
Country | Name | City | State |
---|---|---|---|
Australia | Jullums Lismore Aboriginal Medical Service | Lismore | New South Wales |
Australia | Pangula Mannamurna Aboriginal Corporation | Mount Gambier | South Australia |
Australia | Port Lincoln Aboriginal Health Service | Port Lincoln | South Australia |
Australia | Walhallow Aboriginal Corporation | Quirindi | New South Wales |
Lead Sponsor | Collaborator |
---|---|
Kirby Institute | Flinders University, South Australian Health and Medical Research Institute |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | HCV Transmission networks within the Aboriginal community | HCV viral genome for will be sequenced for all participants from their screening sample. The sequences ill be used for develop a phylogenetic tree which can be used to determine transmission networks within the study population. | At screening for all participants | |
Primary | Change in Hepatitis C prevalence | Change in the proportion of people with current HCV infection (HCV RNA positive) | Week 0 to week 144 | |
Secondary | Change in Hepatitis C incidence | Change in HCV incidence will be calculated using person-time of observation. | Week 0 to week 144 | |
Secondary | DAA uptake | Proportion with HCV infection initiating DAA therapy | To week 144 | |
Secondary | Treatment response rate (SVR12 rate) | Overall SVR12 rate in those who commence treatment | From week 0 to Week 144 | |
Secondary | HCV reinfection incidence post treatment | Participants will be assessed six monthly post end of treatment for HCV recurrence. | 6 monthly from end of treatment until week 144 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 |